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Role of Apaf-1 in Melanoma Drug Resistance and Apoptosis
To the Editor:
The inability to undergo apoptosis in response to chemo-
therapy and other external stimuli poses a selective advan-
tage for tumor progression, metastasis formation as well as
resistance to therapy in melanoma (Soengas and Lowe,
2003). Recently, Apaf-1, known to be critically involved in
the mitochondrial apoptotic pathway, was described as
being frequently downregulated in melanoma primary and
metastatic cell lines on protein and RNA by Soengas et al
(2001), which was suggested as a therapeutic tool in
melanoma treatment. A negative correlation of Apaf-1 to
malignancy, drug resistance, and tumor progression in
melanoma and other tumors has also been shown by other
groups (Jia et al, 2001; Fu et al, 2003; Baldi et al, 2004). In
addition, a higher frequency of allelic imbalance of the Apaf-
1 locus in metastatic compared with primary melanoma was
discovered (Watanabe et al, 2003; Fujimoto et al, 2004). In
contrast to these studies, our experiments using the drug-
sensitive parental melanoma cell line MeWo, and its various
resistant sublines show that Apaf-1 expression is not relat-
ed to apoptosis deficiency and drug resistance.
We have analyzed Apaf-1 expression in relation to
chemoresistance and apoptosis upon drug treatment in a
well-characterized melanoma cell system (Kern et al, 1997;
Lage et al, 1999; Helmbach et al, 2002; Wittig et al, 2002)
of drug-sensitive and -resistant variants, all generated
from a parental melanoma cell line by continuous drug ex-
posure to cisplatin (MeWoCis1), etoposide (MeWoEto1), fot-
emustine (MeWoFote40), and vindesine (MeWoVin5) (Kern
et al, 1997).
In all MeWo cells, no relevant mutation of p53 was de-
tected (data not shown). Drug-resistant variants differ with
respect to DNA repair (Lage et al, 1999) and differential
apoptotic response toward drug exposure (Helmbach et al,
2002). Apoptotic features have been analyzed at a corre-
sponding cell survival rate (25% [IC75] and 5% [IC95]) upon
drug treatment. In contrast to sensitive cells, a marked
apoptosis deficiency was observed in etoposide-resistant
cells including characteristics of apoptotic cell death such
as DNA fragmentation (Fig 1B, lanes 3 and 4), PARP cleav-
age, and effector-caspase activation. In addition, cyto-
chrome c release was strongly reduced and caspase-9
activation was not found compared with sensitive cells
(Helmbach et al, 2002). Despite the significant apoptosis
deficiency observed, there was no differential Apaf-1 ex-
pression on the protein level compared with sensitive cells
(Fig 1A, lane 3). Although cisplatin-resistant cells expressed
significantly higher levels of Apaf-1 than sensitive cells (Fig
1A, lane 2), caspase-9 activation as well as effector-
caspase activation were slightly reduced (Helmbach et al,
2002). Furthermore, the final DNA fragmentation was not
significantly altered in cisplatin-resistant cells (Fig 1B, lanes
1 and 2). Furthermore, in fotemustine-resistant cells, where
no differential expression of Apaf-1 was observed (Fig 1A,
lane 4), DNA fragmentation upon fotemustin exposure was
markedly increased (Fig 1B, lanes 5 and 6). Vindesine-
resistant cells exhibited a strong upregulation of Apaf-1 on
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(A) Western blot analysis of Apaf-1 in whole-cell lysate of drug-sensitive
melanoma MeWo cells (lane 1) and their drug-resistant sublines: cisp-
latin resistant (lane 2), etoposide resistant (lane 3), fotemustin resistant
(lane 4), and vindesin resistant (lane 5). The monoclonal mouse anti-
Apaf-1 antibody was kindly provided by Yuri Lazebnik. Equal amounts
of protein were confirmed by detection of b-actin. (B) DNA fragmen-
tation is induced at corresponding survival rates, 25% [IC75] (black bar)
and 5% [IC95] (gray bar) in sensitive and resistant cells upon drug
treatment using histone-associated DNA fragments (mono- and
oligonucleosomes) released from nuclear fractions of drug-treated
cells that were quantified using a Cell Death Detection ELISA (Roche,
Penzberg, Germany) according to the manufacturer’s instructions. Cells
were treated for 72 h. The respective drug concentrations are shown
below the bars. Data were normalized against the control and inter-
preted as the nucleosome enrichment factor. Standard deviations were
below 8% in all sets of experiments.
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protein level (Fig 1A, lane 5). But no apoptosis deficiency,
associated with DNA fragmentation, could be observed
compared with sensitive cells (Fig 1B, lanes 7 and 8).
Taken together, these observations demonstrate that in
this melanoma cell system of drug-sensitive and -resistant
variants, Apaf-1 expression does not allow to predict
chemosensitivity, as was suggested by Soengas et al
(2001) and Baldi et al (2004). Furthermore, apoptosis defi-
ciency is not associated with reduction of Apaf-1. In con-
trast, there are two drug-resistant sublines (MeWoCis and
MeWoVin) that show a strong upregulation of Apaf-1 on the
protein level compared with sensitive cells. Both lines
showed no significant increase in DNA fragmentation upon
cisplatin or vindesine treatment compared with sensitive
cells. Furthermore, two drug-resistant lines without signif-
icant differential Apaf-1 expression demonstrated different
apoptotic activity upon drug treatment. Whereas etoposide-
resistant cells present a marked reduction of DNA frag-
mentation, fotemustine-resistant cells show an increase.
Our data strongly support the results of Zanon et al
(2004), who investigated Apaf-1 expression in a large panel
of human melanoma and assessed cellular response to
several proapoptotic agents in tumors expressing or lacking
Apaf-1. The authors showed that the response of various
human melanoma cells to different apoptotic agents was
independent of the Apaf-1 phenotype.
We suggest that specific regulation of the apoptotic cas-
cade is strongly dependent on the cell type and the apo-
ptotic stimulus, and differs between different cytostatic
drugs. Because of further apoptosome-independent apo-
ptotic molecules, loss of Apaf-1 might be bypassed and
does not necessarily cause apoptosis deficiency. Con-
versely, an increase of Apaf-1 does not automatically lead to
drug sensitivity.
The data presented here are results obtained on cell
clones selected in vitro from a single parental cell line, and
therefore they cannot be generalized. Nevertheless, these
results clearly show no significant correlation between
Apaf-1 expression in melanoma and malignancy. This is in
contrast to several investigations in the recent past that
showed reduced Apaf-1 expression with tumor progression.
In our melanoma cell system, however, Apaf-1 levels are
clearly not predictive of drug sensitivity, which suggests that
the earlier findings cannot be generalized either. Finally, the
influence of Apaf-1 expression on patient survival still re-
mains as a critical question.
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